JACC in a Flash

The Most Popular JACC Journals Content From 2023

The Most Popular JACC Journals Content From 2023

The JACC Journals' Best of 2023 lists highlight some of the most impactful and practice-changing science published across all 10 journals, providing a glimpse at the topics readers and listeners found most compelling. See each Journal's most read articles based on combined views and downloads on JACC.org and ScienceDirect.com, the most talked about articles according to Altmetrics, and the most listened to podcasts. Click here to access all the lists.

Featured topics and Editors' Picks from all of ACC's JACC Journals.

Journal of the American College of Cardiology
Long-Term Inclisiran Treatment Well Tolerated in Diverse Population of Patients With Dyslipidemia

Long-term treatment with inclisiran was found to be well  tolerated in a diverse population, without new safety signals, supporting the safety of inclisiran in patients with dyslipidemia, according to a study published in JACC.

R. Scott Wright, MD, FACC, et al., conducted a post hoc analysis of participants in both completed and ongoing ORION trials, including 3,576 patients treated with 300 mg inclisiran sodium for up to six years and 1,968 patients treated with placebo for up to 1.5 years. The majority of participants were diagnosed with atherosclerotic cardiovascular disease (ASCVD) and were taking a statin. The authors analyzed exposure-adjusted incidence rates and Kaplan-Meier estimates of the cumulative incidence of reported treatment-emergent adverse events, abnormal laboratory measurements and incidence of antidrug antibodies.

Results showed that treatment-emergent adverse events that were serious or led to discontinuation – hepatic, muscle and kidney events, incident diabetes, elevations of creatine kinase or creatinine accrued – were comparable for up to 1.5 years, with similar trends continuing for inclisiran beyond the period with available placebo data. Fewer major cardiovascular events were reported as treatment-emergent adverse events in the inclisiran group during this period.

In addition, treatment-induced antidrug antibodies were uncommon with inclisiran (4.6%), with few of these cases persistent (1.4%). This complication was not associated with greater incidence of serious treatment-emergent adverse events or drug discontinuation.

In an accompanying editorial comment, Christie M. Ballantyne, MD, FACC, Abdul Mannan Khan Minhas, MD, and Carl E. Orringer, MD, FACC, write, "Inclisiran is a promising new therapy with the advantages of less-frequent dosing, robust LDL-C reduction, good tolerability, and a favorable safety profile. Large ASCVD outcomes trials will help us to better determine whether this agent will safely and effectively reduce ASCVD risk."

Wright RS, Koenig W, Landmesser U, et al. J Am Coll Cardiol 2023;82:2251-61.

Journal of the American College of Cardiology
How Are Novel Imaging Techniques Helping the CHD Population?

Cardiac imaging technologies are increasing rapidly and are becoming increasingly important in helping the growing congenital heart disease (CHD) population who are being treated with more complex surgical and catheter-based procedures, according to a JACC Scientific Statement published in JACC.

Journal of the American College of Cardiology
Paper Examines Importance of Better Integrating APPs into CICU Care

Advanced practice providers (APPs) are a vital group in the  multidisciplinary care needed to manage the complex and evolving populations in the cardiac intensive care unit (CICU) and could be leveraged to improve patient care, according to an article published in JACC.

Journal of the American College of Cardiology
Study Explores Stress, Depression Levels in Women Who Have MI-CAD vs. MINOCA

Stress and depression are common among women at the time of myocardial infarction (MI) and for two months after, and women with MI  and obstructive coronary artery disease (MI-CAD) may have higher stress levels than those with MI with nonobstructive coronary arteries (MINOCA), according to a study published in JACC.

Journal of the American College of Cardiology
New AFib Diagnosis Could Increase Cognitive Impairment, Including Dementia

A diagnosis of atrial fibrillation (AFib) was associated with an increased risk of mild cognitive impairment (MCI) and progression to dementia, according to a study published in JACC: Advances.

Journal of the American College of Cardiology
How Can Novel Imaging Improve Clinical Outcomes in Systemic Inflammatory Diseases?

The integrated application of novel multimodality imaging techniques may improve diagnostic precision for the screening and monitoring of disease activity for patients with systemic inflammatory diseases (SIDs), according to a JACC Scientific Statement published in JACC.

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Atherosclerotic Disease (CAD/PAD)

Keywords: Cardiology Magazine, ACC Publications, Coronary Artery Disease, Depression, Dyslipidemias, Dyslipidemia

< Back to Listings